
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda
Today, a brief rundown of news involving Arvinas and Biogen, as well as updates from Merck & Co., Entrada Therapeutics and Valneva that you may have missed. Arvinas will lay off about a third of its workforce and scrap a pair of anticipated Phase 3 …